Press Release

14 Apr

Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders

April 14, 2023
Posted by Jitendra

PALO ALTO, CALIFORNIA – April 14, 2023 (GLOBE NEWSWIRE) - Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (OTC Market: SRNEQ) (“Sorrento”), announced today that the Company’s 2023...

05 Apr

Press Release

Scilex Holding Company Announces Postponement of Annual Meeting of Stockholders

April 5, 2023
Posted by Jitendra

PALO ALTO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company(Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (OTC Market:SRNEQ) (“Sorrento”), announced today that the Company’s 2023 Annual Meeting of...

27 Mar

Press Release

Scilex Holding Company Reports Substantial Underreporting of More Than 44 Million Shares of its Common Stock by Brokerage Firms for the Upcoming Annual Meeting of Stockholders Scheduled for April 6, 2023 and Issues a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

March 26, 2023
Posted by Jitendra

PALO ALTO, CALIFORNIA – March 27, 2023 (GLOBE NEWSWIRE) - Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (OTC Market: SRNEQ) (“Sorrento”), announced today that there are more...

21 Mar

Press Release

Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products

March 21, 2023
Posted by Jitendra

Proceeds from the financing commitment will be used to enhance the launch and commercialization of Scilex’s three FDA-approved non-opioid pain management products (ZTlido®, Gloperba® and ElyxybTM) for the treatment of...

08 Mar

Press Release

Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment

March 8, 2023
Posted by Jitendra

CH Trading Group will serve as exclusive territories distributor in the Middle East and North Africa countries with US $105 million minimum purchase commitment.

27 Feb

Press Release

Scilex Holding Company announces the commercial launch of ELYXYB^TM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

February 27, 2023
Posted by Jitendra

ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market...

18 Feb

Press Release

Sorrento Posts Form 8937 to Supplement its Previously Issued
“FAQ” Regarding the Dividend of Scilex Holding Company Common
Stock (Nasdaq: SCLX, “Scilex”)

February 18, 2023
Posted by Jitendra

SAN DIEGO, February 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq:SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previouslyissued “Frequently Asked Questions” document under the...

13 Feb

Press Release

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

February 13, 2023
Posted by Ulisses

Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for...

12 Feb

Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB^TM in the U.S. and Canada for the acute treatment of migraine

February 12, 2023
Posted by Jitendra

ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The acute migraine drug market size...

04 Feb

Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders

February 4, 2023
Posted by Jitendra

PALO ALTO, February 4, 2023 /Newswire/ -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused...

Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders

Scilex Holding Company Announces Postponement of Annual Meeting of Stockholders

Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products

Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment

Scilex Holding Company announces the commercial launch of ELYXYB^TM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

Sorrento Posts Form 8937 to Supplement its Previously Issued
“FAQ” Regarding the Dividend of Scilex Holding Company Common
Stock (Nasdaq: SCLX, “Scilex”)

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB^TM in the U.S. and Canada for the acute treatment of migraine

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch

Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024

Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates